333 related articles for article (PubMed ID: 33761896)
1. EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
Miyanaga A; Matsumoto M; Beck JA; Horikawa I; Oike T; Okayama H; Tanaka H; Burkett SS; Robles AI; Khan M; Lissa D; Seike M; Gemma A; Mano H; Harris CC
BMC Cancer; 2021 Mar; 21(1):310. PubMed ID: 33761896
[TBL] [Abstract][Full Text] [Related]
2. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
Li Y; Li Y; Zhang H; Shi R; Zhang Z; Liu H; Chen J
BMC Pulm Med; 2021 Jun; 21(1):190. PubMed ID: 34090412
[TBL] [Abstract][Full Text] [Related]
3. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
4. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
Clin Cancer Res; 2011 Apr; 17(8):2140-8. PubMed ID: 21415216
[TBL] [Abstract][Full Text] [Related]
5. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y
Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977
[TBL] [Abstract][Full Text] [Related]
6. Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC.
Bokhari AA; Lai WY; Le AT; Gabre JL; Chuang TP; Fransson S; Bergman B; Djos A; Chen N; Martinsson T; Van den Eynden J; Doebele RC; Palmer RH; Hallberg B; Umapathy G
Lung Cancer; 2022 Sep; 171():103-114. PubMed ID: 35933914
[TBL] [Abstract][Full Text] [Related]
7. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
8. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
Wong DW; Leung EL; So KK; Tam IY; Sihoe AD; Cheng LC; Ho KK; Au JS; Chung LP; Pik Wong M;
Cancer; 2009 Apr; 115(8):1723-33. PubMed ID: 19170230
[TBL] [Abstract][Full Text] [Related]
9. Circular RNA F-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer.
Tan S; Sun D; Pu W; Gou Q; Guo C; Gong Y; Li J; Wei YQ; Liu L; Zhao Y; Peng Y
Mol Cancer; 2018 Sep; 17(1):138. PubMed ID: 30236141
[TBL] [Abstract][Full Text] [Related]
10. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
[TBL] [Abstract][Full Text] [Related]
11. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.
Dickson MA; Hahn WC; Ino Y; Ronfard V; Wu JY; Weinberg RA; Louis DN; Li FP; Rheinwald JG
Mol Cell Biol; 2000 Feb; 20(4):1436-47. PubMed ID: 10648628
[TBL] [Abstract][Full Text] [Related]
12. Resistance to mutant KRAS
Muraki N; Yamada M; Doki H; Nakai R; Komeda K; Goto D; Kawabe N; Matsuoka K; Matsushima M; Kawabe T; Tanaka I; Morise M; Shay JW; Minna JD; Sato M
Exp Cell Res; 2022 May; 414(1):113053. PubMed ID: 35149086
[TBL] [Abstract][Full Text] [Related]
13. EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling.
Shen J; Meng Y; Wang K; Gao M; Du J; Wang J; Li Z; Zuo D; Wu Y
Cell Signal; 2022 Apr; 92():110264. PubMed ID: 35085771
[TBL] [Abstract][Full Text] [Related]
14. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
[TBL] [Abstract][Full Text] [Related]
15. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line.
Kodama T; Motoi N; Ninomiya H; Sakamoto H; Kitada K; Tsukaguchi T; Satoh Y; Nomura K; Nagano H; Ishii N; Terui Y; Hatake K; Ishikawa Y
J Thorac Oncol; 2014 Nov; 9(11):1638-46. PubMed ID: 25144242
[TBL] [Abstract][Full Text] [Related]
17. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
18. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
[TBL] [Abstract][Full Text] [Related]
19. EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.
Su Y; Yi J; Zhang Y; Leng D; Huang X; Shi X; Zhang Y
J Thromb Thrombolysis; 2024 Jan; 57(1):67-81. PubMed ID: 37940761
[TBL] [Abstract][Full Text] [Related]
20. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
Ma Y; Yu C; Mohamed EM; Shao H; Wang L; Sundaresan G; Zweit J; Idowu M; Fang X
Oncogene; 2016 Nov; 35(47):6132-6142. PubMed ID: 27132509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
